New research from a study of Japanese patients suggests that abrocitinib showed superior efficacy and safety compared to the standard of care (SoC).

Recent findings from the JAK-1 Atopic Dermatitis Efficacy and Safety (JADE) program's Phase 3 trials have unveiled promising insights into the treatment of moderate-to-severe atopic dermatitis (AD) among adults in Japan.

To gauge the cost-effectiveness of abrocitinib in this population, the study researchers conducted a comprehensive using a hybrid decision tree and Markov model, with the goal of capturing both initial treatment and long-term maintenance phases of AD management. They derived key clinical inputs from a Bayesian network meta-analysis of pivotal trials from the JADE program, supplemented by data from the JADE EXTEND trial. They also sourced response-specific utility inputs from the relevant literature. Resource use, costs, and productivity inputs were informed by Japanese claims analysis, literature reviews, public documents, and expert opinions.

According to the results, over a lifetime horizon, abrocitinib showed a mean gain of 0.75 quality-adjusted life years (QALYs) with incremental costs and an resulting incremental cost-effectiveness ratio (ICER) of ¥3,034,514 ($23,076.50 U.S.) per QALY versus SoC. From a payer perspective, however, ICER rose to ¥5,983,495 ($45,502.6) per QALY. Treatment-specific, response-based utility weights, drug costs, and productivity-related inputs significantly influenced the results, according to results from sensitivity and scenario analyses.

Source: Tanaka A, et al. Journal of the Japanese Dermatological Association. April 22, 2024. Doi.org/10.1111/1346-8138.17234